An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome
Badiu et al. • 2023 • European Congress of Endocrinology
© 2024 Corcept Therapeutics, Incorporated
https://corcept.com/wp-content/uploads/2023/05/AACE2023-2.pdf
Donegan et al. • 2023 • AACE 2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias et al. • 2023 • AACE 2023
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing Syndrome
Moraitis et al • 2022 • ENDO 2022 Annual Meeting
Impact of mifepristone on liver function and liver steatosis in patients with Cushing Syndrome
East et al • 2022 • ENDO 2022 Annual Meeting
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome
Moritis et al • 2022 • European Congress of Endocrinology
Mifepristone Use in Hypercortisolism from an Unknown Source: A Case Study
Brown et al • 2022 • American Association of Clinical Endocrinology (AACE) Annual Meeting
When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis
Aresta et al • 2021 • Endocr Pract.
Hidden hypercortisolism: a too frequently neglected clinical condition
Giovanelli et al • 2021 • J Endocrinol Invest.
Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search
Isaac Sachmechi, MD, FACE, FACP; Sanna Salam; Muhammad Umair, MD; Kathleen Wade Tarnowski, MSc • 2021 •